Patents by Inventor Laure Dumoutier

Laure Dumoutier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-GARP protein
    Patent number: 11230603
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: January 25, 2022
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20200181276
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • Antibody against a complex between human GARP and latent TGF-?
    Patent number: 10604579
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: March 31, 2020
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van Der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20190016811
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-ß and uses thereof.
    Type: Application
    Filed: May 9, 2018
    Publication date: January 17, 2019
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van Der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody
    Patent number: 10000572
    Abstract: The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: June 19, 2018
    Assignees: UNIVERSITÉ CATHOLIQUE DE LOUVAIN, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld
  • ANTI-GARP PROTEIN AND USES THEREOF
    Publication number: 20160272717
    Abstract: The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-? and uses thereof.
    Type: Application
    Filed: August 1, 2014
    Publication date: September 22, 2016
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian Van De Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
    Patent number: 7972833
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: July 5, 2011
    Assignee: Wyeth LLC
    Inventors: Laure Dumoutier, Jamila Louahed, Jean-Christophe Renauld
  • Method for identifying a substance which mediates interaction between interleukin 22 and an interleukin 22 receptor
    Patent number: 7846652
    Abstract: Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: December 7, 2010
    Assignee: Wyeth
    Inventors: Jean-Christophe Renauld, Diane Lejeune, Laure Dumoutier
  • Isolated Soluble IL-TIF/IL-22 Receptor or Binding Protein Which Binds to IL-TIF/IL-22 and Uses Thereof
    Publication number: 20090311802
    Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
    Type: Application
    Filed: July 30, 2009
    Publication date: December 17, 2009
    Inventors: Jean-Christophe Renauld, Laure Dumoutier
  • Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
    Publication number: 20080213881
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Application
    Filed: September 21, 2007
    Publication date: September 4, 2008
    Inventors: Laure Dumoutier, Jamila Louahed, Jean-Christophe Renauld
  • Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
    Publication number: 20080064096
    Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
    Type: Application
    Filed: September 7, 2007
    Publication date: March 13, 2008
    Inventors: Jean-Christopher Renauld, Laure Dumoutier
  • Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
    Patent number: 7268223
    Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: September 11, 2007
    Assignee: Wyeth
    Inventors: Jean-Christophe Renauld, Laure Dumoutier
  • Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
    Publication number: 20070104681
    Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
    Type: Application
    Filed: May 4, 2006
    Publication date: May 10, 2007
    Inventors: Jean-Christopher Renauld, Laure Dumoutier
  • Method for influencing kinase pathways with IL-22
    Publication number: 20060257408
    Abstract: Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.
    Type: Application
    Filed: July 24, 2006
    Publication date: November 16, 2006
    Inventors: Jean-Christophe Renauld, Diane Lejeune, Laure Dumoutier
  • Isolated nucleic acid molecules encoding T cell derived inducible factors
    Patent number: 7081528
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: July 25, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Laure Dumoutier, Jamila Louhed, Jean-Christophe Renauld
  • Isolated cytokine receptor LICR-2
    Patent number: 7033787
    Abstract: The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: April 25, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean-Christophe Renauld, Helmut Fickenscher, Laure Dumoutier, Simon Hör
  • Isolated cytokine receptor LICR-2
    Publication number: 20050282215
    Abstract: The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.
    Type: Application
    Filed: July 19, 2005
    Publication date: December 22, 2005
    Inventors: Jean-Christophe Renauld, Helmut Fickenscher, Laure Dumoutier, Simon Hor
  • Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
    Publication number: 20050271619
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors. The molecules are implicated in activation of STAT molecules, acute phase proteins, and inflammation.
    Type: Application
    Filed: July 7, 2005
    Publication date: December 8, 2005
    Inventors: Laure Dumoutier, Jean-Christopher Renauld
  • Novel glass II cytokine receptors, and uses thereof
    Publication number: 20040236075
    Abstract: A new class II cytokine receptor has been identified, which comprises an interleukin-22 receptor molecule, and an interleukin-20 receptor &bgr; molecule. The complex binds to cytokines homologous to IL-10, including mda-7 and IL-20. Also described are methods for inhibiting effect of interleukin-20, mda-7, and IL-19 on cells. The latter is especially useful in treatment of, e.g., skin diseases such as psoriasis.
    Type: Application
    Filed: June 23, 2004
    Publication date: November 25, 2004
    Inventors: Laure Dumoutier, Jean-Christophe Renauld
  • Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
    Publication number: 20040180399
    Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
    Type: Application
    Filed: March 11, 2003
    Publication date: September 16, 2004
    Inventors: Jean-Christophe Renauld, Laure Dumoutier